{"id":742170,"date":"2012-11-08T08:30:00","date_gmt":"2012-11-08T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/"},"modified":"2023-03-22T00:04:20","modified_gmt":"2023-03-22T04:04:20","slug":"merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/","title":{"rendered":"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the New Drug Application (NDA) for suvorexant, the<br \/>\n      company&#8217;s investigational insomnia medicine, has been accepted for<br \/>\n      standard review by the U.S. Food and Drug Administration (FDA).<br \/>\n      Suvorexant will be evaluated by the Controlled Substance Staff of the<br \/>\n      FDA during NDA review. If approved by the FDA,\u00a0suvorexant will become<br \/>\n      available after a schedule assessment and determination has been<br \/>\n      completed by the U.S. Drug Enforcement Administration, which routinely<br \/>\n      occurs after FDA approval. The company is continuing with plans to seek<br \/>\n      approval for suvorexant in other countries around the world.\n    <\/p>\n<p>\n      The NDA for suvorexant was based on data from a broad clinical<br \/>\n      development program, including: two pivotal, three-month efficacy trials<br \/>\n      that evaluated the ability of suvorexant to help patients fall asleep<br \/>\n      and stay asleep; a 12-month study, followed by a two-month<br \/>\n      discontinuation phase, that was designed to assess the safety of<br \/>\n      suvorexant, while also evaluating its longer term efficacy and the<br \/>\n      impact of stopping treatment; and two next-day driving studies that<br \/>\n      provided an assessment of residual effects following evening use of<br \/>\n      suvorexant.\n    <\/p>\n<p>\n      &#8220;The discovery and development of innovative medicines that help<br \/>\n      patients is our goal at Merck, and insomnia is a common disorder where<br \/>\n      patients are seeking new treatments,&#8221; said Darryle D. Schoepp, Ph.D.,<br \/>\n      senior vice president and franchise head, Neuroscience and<br \/>\n      Ophthalmology, Merck Research Laboratories. &#8220;Suvorexant is a novel<br \/>\n      mechanism for the treatment of insomnia, and the filing of suvorexant is<br \/>\n      an example of Merck&#8217;s commitment to patients and to scientific<br \/>\n      excellence.&#8221;\n    <\/p>\n<p>\n      Merck researchers developed suvorexant to target and block orexins,<br \/>\n      chemical messengers that help to keep you awake. By temporarily blocking<br \/>\n      the actions of orexins, suvorexant helps to facilitate sleep. If<br \/>\n      approved, suvorexant would be the first in a new class of medicines,<br \/>\n      called orexin receptor antagonists, for use in patients with difficulty<br \/>\n      falling or staying asleep.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50470231&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=9d719c8299049d730fa8220094e66893\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50470231&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=2&#038;md5=eadda140fba6532454c14afe0ea86a1e\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20121108005310r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 908-423-5042<br \/>or<br \/>Lesley        Brown, 267-305-3545<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company&#8217;s investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Suvorexant will be evaluated by the Controlled Substance Staff of the FDA during NDA review. If approved by the FDA,\u00a0suvorexant will become available after a schedule assessment and determination has been completed by the U.S. Drug Enforcement Administration, which routinely occurs after FDA approval. The company is continuing with plans to seek approval for suvorexant in other countries around the world. The NDA for suvorexant was based on data from a broad clinical development program, including: two pivotal, three-month efficacy trials that evaluated the ability of suvorexant to help patients fall asleep and stay asleep; a 12-month study, followed by a two-month discontinuation phase, that was designed to assess<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[55,289],"class_list":["post-742170","news_item","type-news_item","status-publish","hentry","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company&#039;s investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Suvorexant will be evaluated by the Controlled Substance Staff of the FDA during NDA review. If approved by the FDA,\u00a0suvorexant will become available after a schedule assessment and determination has been completed by the U.S. Drug Enforcement Administration, which routinely occurs after FDA approval. The company is continuing with plans to seek approval for suvorexant in other countries around the world. The NDA for suvorexant was based on data from a broad clinical development program, including: two pivotal, three-month efficacy trials that evaluated the ability of suvorexant to help patients fall asleep and stay asleep; a 12-month study, followed by a two-month discontinuation phase, that was designed to assess\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/\",\"name\":\"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-11-08T08:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company's investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administration (FDA). Suvorexant will be evaluated by the Controlled Substance Staff of the FDA during NDA review. If approved by the FDA,\u00a0suvorexant will become available after a schedule assessment and determination has been completed by the U.S. Drug Enforcement Administration, which routinely occurs after FDA approval. The company is continuing with plans to seek approval for suvorexant in other countries around the world. The NDA for suvorexant was based on data from a broad clinical development program, including: two pivotal, three-month efficacy trials that evaluated the ability of suvorexant to help patients fall asleep and stay asleep; a 12-month study, followed by a two-month discontinuation phase, that was designed to assess","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/","name":"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx","datePublished":"2012-11-08T08:30:00+00:00","dateModified":"2023-03-22T04:04:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121108005310r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-fda-acceptance-of-new-drug-application-for-suvorexant-an-investigational-insomnia-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces FDA Acceptance of New Drug Application for Suvorexant, an Investigational Insomnia Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"1ce243e8-f3d4-4bb1-bdc6-f537e750b037","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742170\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742170"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}